{{Rsnum
|rsid=1884677
|Gene=SLC24A4
|Chromosome=14
|position=92377484
|Orientation=minus
|GMAF=0.343
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC24A4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 16.8 | 45.1 | 38.1
| HCB | 5.2 | 30.4 | 64.4
| JPT | 2.7 | 28.6 | 68.8
| YRI | 6.8 | 38.1 | 55.1
| ASW | 10.5 | 43.9 | 45.6
| CHB | 5.2 | 30.4 | 64.4
| CHD | 4.6 | 30.3 | 65.1
| GIH | 5.9 | 33.7 | 60.4
| LWK | 2.7 | 41.8 | 55.5
| MEX | 15.5 | 46.6 | 37.9
| MKK | 17.3 | 44.9 | 37.8
| TSI | 19.6 | 49.0 | 31.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1884677
|Name_s=
|Gene_s=SLC24A4
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.000007. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109459
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1884677
|overall_frequency_n=77
|overall_frequency_d=128
|overall_frequency=0.601562
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=72
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}